The abstract says in general that all 3 of ASMB's CpAMs "display pangenotypic activity, active against major genotypes (A, B, C, and D)." It's not 100% clear but I take that to read the CpAMs were just tested against those genotypes and not all additional GTs.
Also, the one graph just shows antiviral activity in HepAD38 cell line. Not clear if comparable data available in the HepDE19 or HepG2 cell lines referenced in ENTA presentation. But the ASMB abstract doe have a section devoted to G2 cells and it does seem to show clear activity there, though much more so in the 2nd and 3rd gen ASMB drugs. Part of me does wonder if the P2a clinical data from the lead ASMB drug due next year could disappoint given the much better potency of their 2nd and 3rd gen drugs, though the company has stated it's not clear yet how much potency is needed.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.